Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF STAR-001 (LP-184) AS A SINGLE AGENT AND IN COMBINATION WITH SPIRONOLACTONE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM MALIGNANCIES

Next Previous
Trial Profile

A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF STAR-001 (LP-184) AS A SINGLE AGENT AND IN COMBINATION WITH SPIRONOLACTONE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM MALIGNANCIES

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irofulven (Primary) ; Spironolactone (Primary)
  • Indications CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Medulloblastoma
  • Focus Adverse reactions

Most Recent Events

  • 08 Apr 2026 New trial record
  • 27 Mar 2026 According to Lantern Pharma Inc. media release, this trial will be conducted in collaboration with POETIC(the Pediatric Oncology Experimental Therapeutics Investigators Consortium-a multicenter network of 14 leading academic children's cancer centers across the United States, Canada, and Israel.
  • 27 Mar 2026 According to Lantern Pharma Inc. media release, Lantern Pharma Inc. and Starlight Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for STAR-001 in a planned Phase 1 pediatric clinical trial (IND No. 179145).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top